Compare FedEx Corporation (FDX) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FedEx Corporation vs Twist Bioscience Corp — how do they compare? FedEx Corporation trades at $316.87 (market cap $74.78B), while Twist Bioscience Corp trades at $93.31 (market cap $5.76B). The key difference: FedEx Corporation is far larger — about 13× Twist Bioscience Corp's market cap, and FedEx Corporation pays a 1.56% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| FDX | TWST | |
|---|---|---|
Market Cap | $74.78B | $5.76B |
Sector | Industrials | Health |
52-Week High | $338.75 | $102.88 |
52-Week Low | $174.81 | $24.16 |
Enterprise Value | $104.42B | $5.69B |
Dividend Yield | 1.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FedEx (FDX) trades at $313.66, down slightly by 0.03% on the day, with a bearish technical signal from moving averages and ADX indicators. The company reported revenue of $87.93B for 2025, with a net income margin of 4.68%, and has beaten EPS estimates in recent quarters. Recent corporate actions include a dividend payment and a $1.4B sale of its supply chain unit to CMA CGM, aimed at streamlining operations.
The outlook for FDX is mixed; analyst consensus is bullish with a $360.27 price target, but technicals and margin pressures pose risks. Investment opportunities lie in cost-cutting initiatives and steady revenue growth, while risks include competitive threats from Amazon and soft shipping demand. The stock's valuation appears reasonable with a P/E of 16.9.
Twist Bioscience (TWST) trades at $92.61, up 2.5% on the day, with a bullish technical signal and strong analyst support. The company shows improving revenue growth ($377M in 2025, up 20% year-over-year) but continues to report significant losses (-$77.7M net income). Recent AI-driven drug discovery collaborations and product expansions provide growth catalysts, though persistent negative cash flow and insider selling present concerns.
Outlook remains cautiously optimistic with 79% analyst buy ratings and a $91.63 consensus target. Investment opportunity centers on AI-enabled synthetic biology growth, while risks include sustained profitability challenges, cash burn, and competitive pressures in genomics. The stock trades at premium valuations (P/S 13.74) despite negative margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
